NLRP3 and primary progressive multiple sclerosis: Inflammasomes, particularly NLRP3, have been implicated in MS pathophysiology and are considered promising therapeutic targets and biomarkers, especially for PPMS (Boziki et al., 2020; Govindarajan et al., 2020; Malhotra et al., 2020; Lunemann et al., 2021).